No5(4) 2021
Back to the issue
|
DOI 10.37219/2528-8253-2021-5-04 |
Zabolotnyi DI, Меlnikov OF, Timchenko SV, Rylska OG, Pharaon
ІV, Zayets TA,
Zabolotna DD, Smagina TV, Peleshenko NO, Gogunska IV, Musich IM
Clinical and immunological changes in patients with chronic inflammatory
diseases of the upper respiratory tract at different periods after
administration of influenza vaccine.
Message 1. The influence of parenteral influenza vaccination on the clinical
condition and indicators of systemic humoral immunity in patients with
chronic inflammatory diseases of the upper respiratory tract |
Zabolotny Dmitry I
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine. Director
Doctor of Medical Sciences, Professor, Academician of the National Academy
of Medical Sciences of Ukraine
E-mail: amtc@kndio.kiev.ua
https://www.scopus.com/authid/detail.uri?authorId=6701512931
ORCID ID: https://orcid.org/0000-0001-9429-4414
Melnikov Oleg F.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine.
Head of the Laboratory of Pathophysiology and Immunology (with a group of
pathomorphology)
Doctor of Medical Sciences, Professor
E-mail: elenamelnykova@gmail.com
ORCID ID: https://orcid.org/0000-0002-1261-8647
https://www.scopus.com/authid/detail.uri?authorId=7006385903
https://www.scopus.com/authid/detail.uri?authorId=7003452154
Timchenko Sergei V.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine.
Laboratory of Pathophysiology and Immunology (with a group of
pathomorphology)
Leading Researcher
Candidate of Medical Sciences
E-mail: svtim@i.ua
Rylska Oksana G.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Department of Inflammatory Diseases of ENT Organs
Senior Researcher
Email: oxanar@ua.fm
Faraon Inna V
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Laboratory of Pathophysiology and Immunology (with a group of
pathomorphology)
Junior Researcher
E-mail: amtc@kndio.kiev.ua
ORCID ID: 0000-0003-1010-4308
Zayets Tetiana A.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Laboratory of Pathophysiology and Immunology (with a group of
pathomorphology)
Researcher
E-mail: amtc@kndio.kiev.ua
Zabolotna Diana D
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine.
Head of Department of Rhinology and Allergology with a group of radiology
Doctor of Medical Sciences
E-mail: dianazab@ukr.net
ORCID ID: https://orcid.org/0000-0001-7807-8148
Smagina Tetyana V.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”
Department of Rhinology and Allergology with radiology group
Candidate of Medical Sciences
Email: amtc@kndio.kiev.ua
Peleshenko Natalia O.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Department of Inflammatory Diseases of ENT Organs
Senior Researcher
E-mail: peleshenkon@gmail.com
Gogunska Inna V.
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of
National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
Center allergic diseases of the upper respiratory tract
Doctor of Medical Sciences
e-mail: innagogunskaya@gmail.com
ORCID ID: 0000-0001-6952-5057 |
|
Abstract
Topicality: Today, as an assessment of the effectiveness of
vaccination against influenza infection is to determine the level of
antibodies against influenza virus hemagglutinin, which is determined by the
reaction of inhibition of hemagglutination. It is known that the effect of
vaccination with modern drugs is short-lived, compared with what remains
after the disease. Therefore, there is a need for further vaccinations,
which are carried out without taking into account the state of immunity in
those who will be vaccinated. This raises the question of the
appropriateness of this approach in individuals who, according to this
indicator, can already be considered protected from influenza infection and
how often such patients occur in clinical practice.
Material and methods: From the autumn-winter period of 2019 to
November 2020, 32 donors and 32 patients with chronic inflammatory diseases
of the upper respiratory tract chronic inflammatory diseases of the upper
respiratory tract of both sexes who were not vaccinated for 1 year before
the study were examined. Among these patients, 11 were diagnosed with
chronic rhinosinusitis, 9 with chronic tonsillitis, and 12 with chronic
pharyngitis. All patients with chronic inflammatory diseases of the upper
respiratory tract underwent a complete otolaryngological examination prior
to influenza vaccination and were monitored for another 36 weeks thereafter.
Attention was paid to their general clinical condition, cases of
exacerbations of chronic inflammatory diseases of the upper respiratory
tract and the number of episodes of acute respiratory viral infections
during the year before vaccination according to the anamnesis and for the
observation period during the post-vaccination period.
Samples of serum venous blood of donors, as well as persons with chronic
inflammatory diseases of the upper respiratory tract were obtained at the
initial examination, and in vaccinated patients 3, 12 and 36 weeks after
vaccination and stored at -20°C (Ardo, Italy) until the simultaneous
detection of antibodies (Ab) to influenza A and B viruses by
hemagglutination inhibition reaction with human erythrocytes 0 group.
Trivalent influenza inactivated split vaccine Vaxigrip (France) was used
both for vaccination and in the determination of Ab in the blood for
influenza viruses. In all examinations, the titer of anti-influenza Ab and
the content of immune complexes were determined in the sera of patients, and
the content of total IgE was measured in patients with chronic inflammatory
diseases of the upper respiratory tract before and after 12 and 36 weeks.
Statistical processing of the obtained results was performed in accordance
with the recommendations of Glantz.
Results: In 41% of those examined protectively significant titers of
antibodies to hemagglutinins of vaccine strains of influenza virus vaccine
Vaxigrip were detected in the blood. Parenteral vaccination of patients with
chronic inflammatory diseases of the upper respiratory tract against
influenza helped to improve the course of their underlying clinical disease
and reduce their incidence of acute respiratory viral infections within 36
weeks after vaccination. The effect of increasing the level of antibodies to
hemagglutinins of influenza virus remained at the limit of 3 months and
decreased.
Influenza vaccination in patients with chronic inflammatory diseases of the
upper respiratory tract with the presence of most of them at the time of
vaccination of clinically significant protective titers of antibodies to
hemagglutinins vaccine strains of viruses led to an increase in blood in the
long term of the vaccination process levels of immune complex and total IgE
relative to their initial level, while these indicators did not exceed the
limits of their physiological values.
Conclusion: Single parenteral influenza vaccination leads to a
short-term increase in the blood of specific projective antibodies,
improving the clinical condition of patients with inflammatory diseases of
the upper respiratory tract, increasing the level of immune complexes and
total IgE. |
|
Keywords
chronic inflammatory diseases, influenza vaccination, systemic humoral
immunity. |
|
Reference
- Glantz S. [Biomedical statistics]. Moscow: Practice; 1998. 459 p.
[In Russian].
- Grinevich YA, Alferov AN. [Determination of immune complexes in the
blood of cancer patients]. Lab Delo. 1981;(8):493-6. [Article in
Russian].
- Zamanikhina EV, Kladova OV. [Respiratory virus persistence]. Detskie
Infektsii. 2009;(2):36-43. [Article in Russian].
- Kabat E, Mayer M. Experimental immunochemistry. Moscow: Mir; 1968.
680 p. [In Russian].
- Kostinov MP, Gervazieva VB, Balabolkin II. [Circulating immune
complexes during measles vaccination process in children with allergic
diseases]. Immunologiia. 1989;(5):36-8. [Article in Russian].
- Melnikov OF, Zayats TA. [Comparison of radioisotope and
spectrophotometric methods for determining cell cytotoxicity].
Laboratory Diagnostics.
1999;(1):43-5. [Article in Russian].
- Bouvier N.M. The Future of Influenza Vaccines: A Historical and
Clinical Perspective. Vaccines (Basel). 2018;6(3):58. doi:10.3390/vaccines6030058.
- Dhakal S, Klein SL. Host Factors Impact Vaccine Efficacy:
Implications for Seasonal and Universal Influenza Vaccine Programs. J
Virol. 2019;93(21):e00797-19. doi: 10.1128/JVI.00797-19.
- Goodier MR, Lusa C, Sherratt S, Rodriguez-Galan A, Behrens R, Riley
EM. Sustained Immune Complex-Mediated Reduction in CD16 Expression after
Vaccination Regulates NK Cell Function. Front Immunol. 2016;7:384.
doi:10.3389/fimmu.2016.00384.
- Henault J, Riggs JM, Karnell JL, Liarski VM, Li J, Shirinian L, et
al. Self-reactive IgE exacerbates interferon responses associated with
autoimmunity.
Nat Immunol. 2016 Feb;17(2):196-203. doi: 10.1038/ni.3326.
- Kim MJ, Shim DH, Cha H-R, Kim CB, Kim SY, Park JH, et al.
Anaphylaxis Caused by IgE Response to Influenza Vaccination. Allergy
Asthma
Immunol Res. 2020;12(2):359-63. doi: 10.4168/aair.2020.12.2.359.
- McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J
Allergy Clin Immunol. 2018;141(2):463-72. doi:10.1016/j.jaci.2017.12.971.
- Smith-Norowitz TA, Kusonruksa M, Norowitz KB, Joks R, Durkin HG,
Bluth MH. Long Term Persistence of IgE Anti-Influenza Virus Antibodies
in Pediatric and Adult Serum Post Vaccination with Influenza Virus
Vaccine. Int J Med Sci. 2011;8(3):239-44. doi: 10.7150/ijms.8.239.
- Smith-Norowitz TA, Kusonruksa M, Norowitz KB, Joks R, Durkin HG,
Bluth MH. Long-term persistence of IgE anti-influenza A HIN1 virus
antibodies in serum of children and adults following influenza A
vaccination with subsequent H1N1 infection: a case study. J Inflamm Res.
2012;5:111-6. doi:10.2147/JIR.S34152.
|
|
